SiteOne Therapeutics, Inc.

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

SiteOne Therapeutics announced a $100m series C venture capital round on 18 December to fund development of drugs that target the peripheral nervous system in the treatment of pain and other condition

Vertex Pharmaceuticals is looking to replicate the successful franchise model it created in cystic fibrosis with CFTR modulators in a new therapeutics area – pain, where it has spent 25 years advancin

A fortnight or so after Vertex Pharmaceuticals Incorporated ’s VX-548 achieved one of the vanishingly few breakthroughs by a non-opioid painkiller, a start-up has emerged to develop a similarly actin